ReviewTranslational breast cancer research : a journal focusing on translational research in breast cancer2026
Review in Translational breast cancer research : a journal focusing on translational research in breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Somatic BRCA alterations in breast cancer are associated with distinct biological and clinical patterns according to germline BRCA status.ESMO open · 2026Article
- Navigating first- and second-line treatment options in hormone receptor-positive HER2-negative advanced breast cancer.The oncologist · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Breast cancer (BC) remains the most prevalent malignancy in women globally, with hormone receptor-positive (HR Methods: A narrative review was conducted using PubMed, Google Scholar, and abstracts from major oncology congresses [European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), and San Antonio Breast Cancer Symposium]. The search employed terms including "CDK inhibitors", " Key Content and Findings: The review synthesizes data from retrospective studies and clinical trials, revealing consistent trends of shorter PFS and OS in gBRCAm patients treated with CDK4/6i compared to wild-type counterparts. Key mechanisms implicated include co-occurring Conclusions: This review underscores the need for prospective studies to clarify the prognostic and predictive role of gBRCAm in CDK4/6i-treated HR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.